Sanofi Healthcare India Pvt. Ltd. (SHIPL) announced a major expansion of its Global Capability Centre (GCC) in Hyderabad, adding over 2.7 lakh square meters of state-of-the-art workspace within its existing campus in HITEC City. The inauguration ceremony was attended by Duddilla Sridhar Babu, Minister for IT, Industries and Commerce, government of Telangana, along with senior Sanofi executives, underscoring the strategic importance of the expansion for both the company and the state.
Scaling One of India’s Largest Pharma GCCs
Since its inauguration in 2024, Sanofi’s Hyderabad GCC has stood out for its scale, multidisciplinary expertise, and ability to support global end-to-end operations. The centre’s capabilities span artificial intelligence (AI), digital health, intelligent automation, data analytics, and enterprise services. With this expansion, the facility’s employee capacity will increase from approximately 2,600 to nearly 4,500 professionals, making it one of Sanofi’s largest global talent hubs. Furthermore, it positions the Hyderabad site among the top three pharmaceutical GCCs in India.
Strategic Investment in India’s Life Sciences Ecosystem
Sanofi’s Global Capability Centres serve as strategic hubs worldwide, enabling the company to deliver best-in-class enterprise solutions and innovation-driven operations. Backed by a multi-hundred-million-dollar investment, the Hyderabad expansion reflects Sanofi’s long-term commitment to India’s growing life sciences ecosystem and strong digital talent base.
Importantly, the expanded GCC will generate diverse roles across:
*Research & Development
*Digital Innovation & AI
*Data Analytics
*Medical Affairs
*People Services
*Finance and Procurement
*Commercial Operations
As a result, professionals across experience levels will gain access to high-impact career opportunities within a global biopharma organization.
From Medical Services to a Global Innovation Hub
Sanofi established its Hyderabad operations in 2019, initially focusing on Medical Services. Since then, the centre has grown exponentially, delivering advanced services to Sanofi’s global functions and affiliates. Today, the Hyderabad GCC operates as a future-ready global hub, designed with sustainability, inclusivity, and collaboration at its core. The company has reimagined the workplace into a hospitality-inspired environment, encouraging employee well-being, teamwork, and operational excellence. By promoting collaboration and leveraging AI-powered systems, the centre enhances efficiency across the entire pharmaceutical value chain—from research and discovery to manufacturing and supply.
Leadership Perspectives on the Expansion
Madeleine Roach, EVP and Head of Business Operations at Sanofi, emphasized, “As an R&D-driven, AI-powered biopharma company, we remain focused on improving people’s lives. Our Hyderabad GCC supports critical processes across the drug research, development, manufacturing, and access lifecycle. India’s exceptional talent in digital innovation, AI, and data science is accelerating our transformation. We look forward to growing our capabilities further and partnering with Telangana as it sets new benchmarks in life sciences innovation.”
Mrinal Duggal, Head of Hyderabad Global Hub, Sanofi, reaffirmed, “We have delivered on our commitment made in 2024. This expansion strengthens our global capabilities while empowering the local workforce and reinforcing Hyderabad’s position as a premier pharmaceutical and healthcare destination.”
Strengthening Hyderabad’s Position as a Global Biopharma Hub
With this expansion, Sanofi not only scales its global operations but also deepens its integration with India’s digital and life sciences ecosystem. By combining AI, advanced analytics, sustainability, and talent development, the Hyderabad GCC is set to play a critical role in shaping the future of global healthcare innovation. As per the press release, as Hyderabad continues to emerge as a leading life sciences and technology powerhouse, Sanofi’s expanded presence signals strong confidence in India’s ability to drive the next wave of pharmaceutical transformation.
